UK-based Ubiquigent Ltd has appointed two academic specialists to its scientific advisory board to help guide its deubiquitylase enzyme and ubiquitin-proteasome system (UPS)-based drug discovery work. They are Helen Walden and John Davis. Dr Walden is professor of structural biology at the University of Glasgow, UK, and director of the Institute of Molecular Cell and Systems Biology, with more than 20 years’ experience in studying the UPS. Dr Davis is chief scientific officer for the Centre for Medicines Discovery at the University of Oxford, UK, and director of business development for the Alzheimer’s Research UK Drug Discovery Alliance.
Ubiquigent announced the appointments on 5 July 2022.
Copyright 2022 Evernow Publishing Ltd